The invention relates to a slow-release injection containing
bortezomib and topoismerase inhibitors. The slow-release injection is composed of slow-release microspheres and a
solvent, wherein the slow-release
microsphere contains an anticancer effective component selected from
bortezomib and topoismerase inhibitor and a slow-release
adjuvant, and the
solvent is a common
solvent or a special solvent containing suspending agent. The
viscosity of the suspending agent is in the range from 100cp to 3000cp at a temperature
ranging from 20 DEG C to 30 DEG C. The suspending agent is preferably
sodium carboxymethylcellulose. The slow-release
adjuvant is selected from a
copolymer of poly(
phosphate ester) (such as p(LAEG-EOP) and p(DAPG-EOP)) or a
copolymer or a blend of poly(
phosphate ester) and PLA or polifeprosan or
PLGA or poly(
erucic acid dipolymer-
sebacic acid). The topoismerase inhibitor is selected from
camptothecin, hydroxycamptothecine, topoteean, lurtotecan,
irinotecan,
etoposide and
teniposide. The anticancer composition is also formulated as slow-release
implant. After the intratumoral or peritumoral injection or implantation, the effective
blood concentration lasts more than 60 days. Additionally, the slow-release injection can significantly reduce the general
drug reaction and selectively enhance the chemotherapeutic effect, particularly the effect of non-operative treatment such as local radiotherapy. The slow-release injection is used for the treatment of various
solid tumors.